메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma(BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD)regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). Materials and MethodsPatients  20 years of age and pathologically diagnosed with BL or Burkitt-like lymphomawere treated with at least one cycle of R-hyper-CVAD as the first-line treatment in thisstudy. Eligible patients’ case report forms were requested from their physicians to obtainclinical and laboratory data for this retrospective study. ResultsForty-three patients (median age, 51 years) from 14 medical centers in Korea wereanalyzed, none of which were infected with human immunodeficiency virus. The majority ofpatients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rateswere 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete theR-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin,vincristine, methotrexate, and cytarabine were between 60% and 65%, which means lessthan 25% of patients received greater than 80% of the planned dose of each drug. Poorperformance status was related to the lower RDIs of doxorubicin and methotrexate. ConclusionR-hyper-CVAD showed excellent treatment outcomes in patients who were suitable fordose-intense chemotherapy. However, management of patients who are intolerant to adose-intense regimen remains problematic due to the frequent occurrence of treatmentrelatedcomplications.

목차

등록된 정보가 없습니다.

참고문헌 (21)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0